RHYTHM PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $55.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- RHYTHM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $55.70M, a 4.46% decline from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $58.30M, a 16.83% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $49.90M, a 15.49% decline from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $59.05M, a 139.88% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $55.70M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $58.30M 10-K · filed 2026-02-26 | $58.34M 10-K · filed 2025-02-28 |
| 2023-12-31 | $49.90M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $59.05M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $24.61M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $40.65M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $45.26M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $23.61M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $3.59M 10-K · filed 2019-03-08 | |
| 2016-12-31 | $9.42M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |